BBB penetrating drugs market is projected to grow at an annualized rate of ~154% <till 2030>

Roots Analysis has done a detailed study on Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics.”

covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 400+ page report, which features 145+ figures and 205+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html

 

Key Market Insights

• More than 110 drugs, capable of penetrating this elusive barrier are currently being evaluated for the treatment of CNS disorders; there are 35+ technology platforms for the development of BBB penetrant drugs
• Majority of drug candidates are currently in the early stages of development, and are intended for the treatment of neurological conditions; a large proportion of the existing pipeline molecules are biologics
• In order to achieve a competitive edge, several technology developers are presently focusing on the integration of advanced technical features into their proprietary drug development / delivery platforms
• An assessment of 240+ drug developers, focused on Parkinson’s and Alzheimer’s diseases, revealed that many such firms are likely to partner with technology providers in order to leverage their BBB penetration expertise
• Over the years, more than 16,700 patents related to BBB technologies have been filed / granted to various industry and non-industry players, indicating the pace of R&D activity in this burgeoning field of research
• Foreseeing a lucrative future, several private and public investors have invested close to USD 1 billion, across more than 70 funding instances
• Revenues generated from the sales of BBB penetrating drugs are anticipated to be well distributed across different types of molecules, target disease indications and various global regions over time
• In the near-term, the opportunity is likely to be driven by licensing activity driven by the capability of leading BBB penetrating technologies to successfully facilitate drug delivery into the brain

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html

 

Table of Contents

 

1. PREFACE

1.1. Scope of the Report

1.2. Research Methodology

1.3. Chapter Outlines

 

2. EXECUTIVE SUMMARY

 

3. INTRODUCTION

3.1. Chapter Overview

3.2. Structure of the Human Brain

3.3. Global Burden on Neurological Disorders and Impact of Coronavirus Disease (COVID-19)

 

3.4. Strategies for Drug Delivery to the Central Nervous System (CNS)

3.4.1. Invasive Techniques

3.4.1.1. Systemic Administration of Therapeutics

3.4.1.2. Direct Administration of Therapeutics

3.4.1.3. Intracerebral Devices and Implants

 

3.4.2. Non-Invasive Techniques / Approaches

3.4.2.1. Liposomes

3.4.2.2. Exosomes

3.4.2.3. Prodrugs

3.4.2.4. Nanoparticles and Microspheres

3.4.2.5. Novel Formulations and Conjugates

3.4.3. Chemical Delivery Systems

 

3.5. Blood-Brain Barrier (BBB)

3.5.1. Key Historical Milestones

3.5.2. Structure and Key Components

3.5.3. Key Functions

 

3.6. Strategies for Drug Delivery across the BBB

3.6.1. Increasing Permeability by Temporary Disruption of the BBB

3.6.2. Pharmacological Strategies to Facilitate Transport Across the BBB

3.7. Challenges Associated with BBB Penetration and CNS Drug Delivery

 

3.8. Prevalent Trends Related to Non-Invasive BBB Penetration Technologies

3.8.1. Emerging Focus Areas

3.8.2. Key Historical Trends

3.8.3. Geographical Activity

3.9. Concluding Remarks

 

4. MARKET LANDSCAPE: NON-INVASIVE BBB PENETRATION

4.1. Chapter Overview

4.2. Non-Invasive BBB Penetration Technologies: Overall Market Landscape

4.2.1. Analysis by Status of Development

4.2.2. Analysis by Underlying Principle

4.2.3. Analysis by Compatible Pharmacological Molecule(s)

4.2.4. Analysis by Target Receptor(s)

4.2.5. Analysis by Target Disease Indication(s)

4.2.6. Analysis by Patent Availability

4.2.7. Analysis by Licensing Activity

 

4.3. Non-Invasive BBB Penetration Technology Providers: Overall Market Landscape

4.3.1. Analysis by Year of Establishment

4.3.2. Analysis by Company Size

4.3.3. Analysis by Location of Headquarters

 

5. MARKET LANDSCAPE: BBB PENETRATING DRUGS

5.1. Chapter Overview

5.2. BBB Penetrating Drugs: Development Pipeline

5.2.1. Analysis by Phase of Development

5.2.2. Analysis by Type of Molecule

5.2.3. Analysis by Affiliated BBB Penetration Technology

5.2.4. Analysis by Route of Administration

5.2.5. Analysis by Target Disease Indication(s)

5.2.6. Analysis by Therapeutic Area(s)

5.3. BBB Penetrating Drugs: Additional Information

 

5.4. BBB Penetrating Drug Developers: Overall Market Landscape

5.4.1. Analysis by Year of Establishment

5.4.2. Analysis by Company Size

5.4.3. Analysis by Location of Headquarters

5.4.4. Leading Drug Developers: Analysis by Number of Drugs

5.4.5. Leading Drug Developers: 4D Bubble Analysis based on Pipeline Strength, Target Disease Indication and Company Size

5.4.6. Heptagon Representation: Analysis by Phase of Development and Key Disease Indications

5.4.7. Tree Map Representation: Analysis by Key Disease Indications and Size of the Company

 

6. COMPANY PROFILES

6.1. Chapter Overview

6.2. Leading Players based in North America

 

6.2.1. Angiochem

6.2.1.1. Company Overview

6.2.1.2. Technology Overview

6.2.1.3. Product Portfolio

6.2.1.4. Recent Developments and Future Outlook

 

6.2.2. ArmaGen

6.2.2.1. Company Overview

6.2.2.2. Technology Overview

6.2.2.3. Product Portfolio

6.2.2.4. Recent Developments and Future Outlook

 

6.2.3. Denali Therapeutics

6.2.3.1. Company Overview

6.2.3.2. Technology Overview

6.2.3.3. Product Portfolio

6.2.3.4. Recent Developments and Future Outlook

 

6.2.4. ICB International

6.2.4.1. Company Overview

6.2.4.2. Technology Overview

6.5.4.3. Product Portfolio

6.2.4.4. Recent Developments and Future Outlook

 

6.2.5. Lauren Sciences

6.2.5.1. Company Overview

6.2.5.2. Technology Overview

6.2.5.3. Product Portfolio

6.2.5.4. Recent Developments and Future Outlook

 

6.3. Leading Players based in Europe

6.3.1. BioArctic

6.3.1.1. Company Overview

6.3.1.2. Technology Overview

6.3.1.3. Product Portfolio

6.3.1.4. Recent Developments and Future Outlook

 

6.3.2. Cyclenium Pharma

6.3.2.1. Company Overview

6.3.2.2. Technology Overview

6.3.2.3. Product Portfolio

6.3.2.4. Recent Developments and Future Outlook

 

6.3.3. Iproteos

6.3.3.1. Company Overview

6.3.3.2. Technology Overview

6.3.3.3. Product Portfolio

6.3.3.4. Recent Developments and Future Outlook

 

6.3.4. Medesis Pharma

6.3.4.1. Company Overview

6.3.4.2. Technology Overview

6.3.4.3. Product Portfolio

6.3.4.4. Recent Developments and Future Outlook

 

6.3.5. Ossianix

6.3.5.1. Company Overview

6.3.5.2. Technology Overview

6.3.5.3. Product Portfolio

6.3.5.4. Recent Developments and Future Outlook

 

6.3.6. Vect-Horus

6.3.6.1. Company Overview

6.3.6.2. Technology Overview

6.3.6.3. Product Portfolio

6.3.6.4. Recent Developments and Future Outlook

 

6.4. Leading Players based in Asia-Pacific

6.4.1. JCR Pharmaceuticals

6.4.1.1. Company Overview

6.4.1.2. Technology Overview

6.4.1.3. Product Portfolio

6.4.1.4. Recent Developments and Future Outlook

 

7. TECHNOLOGY COMPETITIVENESS ANALYSIS

7.1. Chapter Overview

7.2. Methodology and Key Parameters

7.3. BBB Penetration Technologies: Platform Competitiveness Analysis

 

8. NON-INVASIVE BBB PENETRATION TECHNOLOGIES: POPULAR APPROACHES

8.1. Chapter overview

8.2. Receptor Mediated Transcytosis (RMT)

8.2.1. Type of Target Receptors

8.2.1.1. Diphtheria Toxin Receptor

8.2.1.2. Insulin Receptor and Insulin-like Growth Factor Receptor

8.2.1.3. Low Density Lipoprotein Receptor-Related Proteins (LRP-1 and LRP-2)

8.2.1.4. Transferrin Receptor

 

8.2.2. Types of RMT Approaches

8.2.2.1. Bispecific Antibody-based Approach

8.2.2.2. Molecular Trojan Horse-based Approach

8.2.2.2.1. Important Considerations for Designing Molecular Trojan Horses

8.2.2.2.2. Considerations for Designing a Trojan Horse Liposome (THL)

8.2.2.2.3. Popular Conjugation Strategies

8.2.2.2.3.1. Direct Coupling Approach

8.2.2.2.3.2. Nanoparticles-based Approach

 

8.3. Increasing the Permeability of the BBB

8.3.1. Use of Ultrasound Waves

8.3.2. Use of High-Frequency Electric Field

 

8.4. Passive Diffusion

 

8.5. Novel Approaches

8.5.1. Cell Penetrating Peptides

8.5.2. Macrocycles

8.5.3. Organ-on-a-Chip Technology

 

9. PARTNERSHIPS AND COLLABORATIONS

9.1. Chapter Overview

9.2. Partnership Models

 

9.3. Non-Invasive BBB Technologies and Drugs: List of Partnerships and Collaborations

9.3.1. Analysis by Year of Partnership

9.3.2. Analysis by Type of Partnership

9.3.3. Analysis by Year and Type of Partnership

9.3.4. Analysis by Type of Partner

9.3.5. Analysis by Focus Area

9.3.6. Analysis by Type of Molecule

9.3.7. Analysis by Target Disease Indication

9.3.8. Most Active Players: Analysis by Number of Partnerships

9.3.9. Most Popular Technologies: Analysis by Number of Partnerships

9.3.10. Regional Analysis

9.3.11. Intercontinental and Intracontinental Agreements

 

10. ANALYSIS OF RECENT LICENSING AGREEMENTS

10.1. Chapter Overview

10.2. Licensing Agreements: Definition and Importance in Pharmaceutical Industry

 

10.3. Types of Licensing Agreements

10.3.1. Out-Licensing Agreements

10.3.2. In-Licensing Agreements

 

10.4. Components of Licensing Agreements

 

10.5. Recent Examples of BBB-R